title: Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.
abstract: BACKGROUND
  Preoperative Ca-125 level has been used as a predictor of optimal cytoreduction in advanced ovarian carcinoma. Yet, controversy exists regarding the ability of the tumor marker to predict optimal debulking and moreover of the proper cut-off limit to do so.
  
  
  METHODS
  The preoperative Ca-125 levels of 426 patients with Stage III/IV ovarian carcinoma from a single institution were correlated with surgical outcome. Optimal was considered the cytoreduction if the largest residual tumor was < or equal to 1 cm in diameter. Receiver operation characteristic (ROC) curve data were combined with interval likelihood ratios at various Ca-125 levels to determine the cut-off level with the maximum prognostic power. Sensitivity, specificity, positive and negative predictive values and accuracy were also calculated.
  
  
  RESULTS
  Preoperative Ca-125 proved to be a reliable predictor for optimal cytoreduction. The area under curve of the ROC curve was 0.89, 98% C.I.=[0.828-0.952], indicating very good discriminating capability. The level of 500 IU/ml was found to have the most predictive power. The sensitivity of Ca-125 at that level was 78.5%, the specificity 89.6%, the positive predictive value 84.2%, the negative predictive value 85.4% and its accuracy 85%. Furthermore, the likelihood ratio for correct discrimination between optimal and sub-optimal cytoreduction, dropped sharply from 6.33, 95% C.I. [5.19-10.91] at the level of 500 IU/ml to 0.58, 95% C.I. [0.21-1.63] at the level of 600 IU/ml.
  
  
  CONCLUSIONS
  Our data indicate that preoperative Ca-125 is a good predictor for optimal cytoreduction. the best threshold for this prediction proved to be 500 IU/ml. These patients may be candidates for neo-adjuvant chemotherapy treatment. Nevertheless, all clinical and radiological findings must be co-evaluated.
authors.affiliation: Department of Gynecology, Metaxa Memorial Cancer Hospital, Piraeus, Greece. vorgiasgeorge@yahoo.gr
authors.forename: George
authors.initials: G
authors.lastname: Vorgias
authors.forename: Christos
authors.initials: C
authors.lastname: Iavazzo
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Savvopoulos
authors.forename: Eva
authors.initials: E
authors.lastname: Myriokefalitaki
authors.forename: Michael
authors.initials: M
authors.lastname: Katsoulis
authors.forename: Nickolas
authors.initials: N
authors.lastname: Kalinoglou
authors.forename: Thrassivoulos
authors.initials: T
authors.lastname: Akrivos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000379:methods; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery*; D011237:Predictive Value of Tests; D011300:Preoperative Care; D012372:ROC Curve
chemical_list: D018394:CA-125 Antigen